Trevi Therapeutics, Inc. (TRVI) Stock Price & Analysis
Trevi Therapeutics, Inc. (TRVI) rose 0.67% to USD 13.59 as of June 10, 2026 at 01:57 UTC, according to Nexqual real-time market data.
TRVI last closed at USD 13.5; the session ranged USD 13.2–13.89 on volume of 855,764 shares. Market capitalization is $1.93B, with a 52-week range of USD 5.41–16.12 (NGM). Source: Nexqual, June 10, 2026 at 01:57 UTC.
Key Statistics (as of June 10, 2026 at 01:57 UTC)
| Price | USD 13.59 |
|---|---|
| Change | ▲ 0.67% (up) |
| Previous Close | USD 13.5 |
| Open | USD 13.65 |
| Day Range | USD 13.2 – 13.89 |
| 52-Week Range | USD 5.41 – 16.12 |
| Volume | 855,764 shares |
| Market Cap | $1.93B |
| Exchange | NGM |
Technical Analysis (TRVI)
Nexqual's technical model rates TRVI "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:57 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.16 (neutral) |
| vs SMA50 | Below (USD 13.88) |
| MACD | -0.11 (negative) |
Analyst Ratings (TRVI)
Wall Street analysts rate TRVI "None" based on 10 analysts, with a mean price target of USD 23.9 (range USD 20–30), per Nexqual as of June 10, 2026 at 01:57 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 23.9 |
| High Target | USD 30 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (TRVI)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.1 ▲ beat |
| 2025-06-30 | USD -0.09 vs est -0.1 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
Financials & Fundamentals (TRVI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -33.59% |
| Debt / Equity | 0.4 |
| Current Ratio | 24.75 |
| Total Cash | $171.78M |
| Total Debt | $682,000 |
| Free Cash Flow | $-28.53M |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
Financial Health Score (TRVI)
Nexqual rates Trevi Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $172M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$45M |
| Efficiency | Critical — ROE -34%, ROA -23.0% |
Ownership (TRVI)
| Insider Ownership | +0.63% |
|---|---|
| Institutional Ownership | +98.30% |
| Shares Outstanding | 141.98M |
| Float | 117.83M |
| Short % of Float | +10.62% |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
Leadership (TRVI)
Trevi Therapeutics, Inc. is led by Jennifer L. Good (age 60), Co-Founder, CEO, President, & Director, per Nexqual as of June 10, 2026 at 01:57 UTC.
| Co-Founder, CEO, President, & Director | Jennifer L. Good (age 60) |
|---|---|
| Co-Founder & Chief Scientific Officer | Thomas R. Sciascia (age 72) |
| Chief Financial Officer & Principal Financial Officer | David C. Hastings (age 64) |
Major Backers & Investors (TRVI)
Notable institutional backers of Trevi Therapeutics, Inc. include NEA Management Company, LLC, Frazier Life Sciences Management, L.P. , FMR, LLC, according to Nexqual as of June 10, 2026 at 01:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| NEA Management Company, LLC | 9.31% |
| Frazier Life Sciences Management, L.P. | 7% |
| FMR, LLC | 5.66% |
| Fidelity | 4.64% |
| Wellington Management | 3.65% |
| Vivo Capital, LLC | 3.59% |
| Marshall Wace LLP | 2.79% |
| Rubric Capital Management LP | 2.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.8% |
| Vanguard Group | 6.94% |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
From Trevi Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
- The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
- Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | USD 3.52 | ▼ 4.61% |
| XFOR | X4 Pharmaceuticals, Inc. | USD 3.85 | ▲ 0.52% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 6.12 | ▲ 1.32% |
| TARA | Protara Therapeutics, Inc. | USD 3.97 | ▼ 4.57% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:57 UTC. This page is informational and not investment advice.